de Gage SB, et al. - Using the French national health insurance database, the risk of serious liver injury associated with new use of serotonin and noradrenaline reuptake inhibitors (SNRIs: venlafaxine, milnacipran, duloxetine) and ‘other antidepressants’ compared with selective serotonin reuptake inhibitors (SSRIs: fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram) in real-life practice was estimated. In this cohort study, researchers included 4,966,825 individuals (aged 25 years and older) with a first reimbursement of SSRIs, SNRIs or ‘other antidepressants’ between January 2010 and June 2015. No increased risk of serious liver injury was evident following initiation of SNRIs or ‘other antidepressants’ compared with SSRIs in real-life practice This suggests an inherent lack of difference in risk between the drug classes, or the fact that individuals with higher susceptibility to drug-induced liver injury are not prescribed drugs considered to be more hepatotoxic.